Tom O'Shea

Dr. O’Shea joined Cyteir in 2018 and brings over 25 years of R&D experience in the pharmaceutical industry with a proven track record of successfully driving preclinical research and development across diverse therapeutic areas including oncology.

Prior to joining Cyteir, Dr. O’Shea was the US Head of Drug Metabolism & Pharmacokinetics (DMPK) in Sanofi and Vice President of DMPK and Pharmaceutics in Genzyme. In these roles, he contributed to the successful global registration of several drugs including Mozobil, Kynamro and Cerdelga. Dr O’Shea has also contributed to numerous investigational new drug applications and is a co-inventor of venglustat currently in clinical development for the treatment of multiple indications caused by lysosomal dysfunction. Dr. O’Shea began his pharmaceutical career in Searle where he held roles of increasing responsibility through a merger with Pharmacia and subsequent acquisition by Pfizer. Following a role in AstraZeneca, Dr. O’Shea joined Genzyme in 2005 to advance the small molecule portfolio. Dr. O’Shea holds a PhD in Chemistry from Dublin City University.